Funding for this research was provided by:
Weston Brain Institute (TR150199)
Text and Data Mining valid from 2020-03-16
Received: 14 January 2020
Accepted: 24 February 2020
First Online: 16 March 2020
: Human tissue acquisition, processing, and cell line generation was approved by the UBC Research Ethics Board. Animal use was approved by the UBC Research Ethics Board.
: No applicable.
: SA is a senior scientist at adMare BioInnovations; FSS is an associate scientist at adMare BioInnovations; JT is an associate scientist at adMare BioInnovations; JBJ is the Principal Consultant for JAQJAM Consulting and Chief Executive Officer of Protaxis Therapeutics Inc.; HHF has service agreements through UCSD for consulting activities with TauRX, Arkuda Therapeutics, Axon Neurosciences, Tau Consortium for Scientific Advisory Board, Roche/Genentech Pharmaceuticals for DMC and DSMB activities; HHF and IRM are co-patent holders, Detecting and Treating Dementia Serial Number 12/3–2691 U.S. Patent No. PCT/US2007/07008. Washington, DC: U.S. Patent and Trademark Office; IRM receives a stipend for activities on the scientific advisory board for Prevail Therapeutics and holds a patent related to treating dementia with <i>GRN</i> mutations.